Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer
暂无分享,去创建一个
S. Nomura | A. Sato | A. Ohtsu | T. Satoh | T. Yoshino | T. Nakajima | T. Nishina | N. Fuse | Y. Komatsu | T. Esaki | H. Taniguchi | E. Shinozaki | H. Bando | M. Wakabayashi | T. Masuishi | D. Kotani | Koji Takahashi | H. Ono | N. Hirano | N. Fujishiro
[1] K. Muro,et al. Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Wason,et al. Two-stage phase II oncology designs using short-term endpoints for early stopping , 2017, Statistical methods in medical research.
[3] P. Quirke,et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Ando,et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] R. Bernards,et al. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility , 2016, Cell.
[6] B. Kermani,et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.
[7] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[8] T. Yamanaka,et al. Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics). , 2015 .
[9] Hartmut Link,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[10] M. Tzardi,et al. BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome , 2013, PloS one.
[11] P. Gibbs,et al. PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 , 2013, Clinical Cancer Research.
[12] Albert C. Koong,et al. BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon: An Aggressive Adenocarcinoma With Poor Survival, Mucinous Differentiation, and Adverse Morphologic Features , 2012, The American journal of surgical pathology.
[13] Y. Yatabe,et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer , 2011, British Journal of Cancer.
[14] 陆星华,et al. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2001 .
[15] Melvin J. Yu,et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. , 2001, Cancer research.
[16] P. Simmonds,et al. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2000, BMJ : British Medical Journal.